Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.6050
+0.0628 (11.58%)
Aug 15, 2025, 10:51 AM - Market open
Plus Therapeutics Employees
Plus Therapeutics had 21 employees as of December 31, 2024. The number of employees increased by 1 or 5.00% compared to the previous year.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
$247,905
Profits / Employee
-$1,291,333
Market Cap
36.60M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 21 | 1 | 5.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 3 | 21.43% |
| Dec 31, 2021 | 14 | 2 | 16.67% |
| Dec 31, 2020 | 12 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PSTV News
- 3 hours ago - Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements - GlobeNewsWire
- 18 hours ago - Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 1 day ago - Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference - GlobeNewsWire
- 15 days ago - Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic - GlobeNewsWire
- 23 days ago - Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewsWire
- 5 weeks ago - Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire